Merck & Co. has achieved a third consecutive Phase 3 trial win for its oral PCSK9 inhibitor in hyperlipidemia, reinforcing its push towards broader regulatory discussions and market expansion. The drug’s success continues to validate oral administration of PCSK9 inhibition as a viable alternative to injectable therapies, addressing a substantial unmet need for lipid management in high-risk patients. Merck plans to engage in regulatory talks, aiming to solidify labeling and approval pathways for wider indications. This milestone bolsters Merck’s cardiovascular portfolio and intensifies competition in the cholesterol-lowering therapeutic space.